Global Spinal Muscular Atrophy Medicine Market Growth 2026-2032
The global Spinal Muscular Atrophy Medicine market size is predicted to grow from US$ 5596 million in 2025 to US$ 15629 million in 2032; it is expected to grow at a CAGR of 18.5% from 2026 to 2032.
Spinal Muscular Atrophy Medicine refers to a general category of pharmaceutical products used for the treatment of spinal muscular atrophy, a rare inherited neuromuscular disease. Spinal muscular atrophy is an autosomal recessive disorder primarily caused by homozygous deletion or mutation of the survival motor neuron 1 gene, leading to deficiency of survival motor neuron protein function, which in turn triggers degeneration of spinal cord anterior horn motor neurons and results in progressive muscle weakness and atrophy in patients. The severity of the disease is inversely correlated with survival motor neuron 2 gene copy number, with fewer copies leading to more severe disease. From an industrial attribute perspective, Spinal Muscular Atrophy Medicine sits at the intersection of gene therapy, antisense oligonucleotide technology, small molecule drug development, and rare disease treatment. Three disease modifying therapies have been approved globally, each increasing functional survival motor neuron protein levels through different mechanisms. The core value of these drugs lies in fundamentally changing the natural history of spinal muscular atrophy, particularly enabling near normal motor development in children treated during the presymptomatic stage.
Market Development Opportunities and Main Drivers
The global expansion of newborn screening programs has promoted early diagnosis of spinal muscular atrophy, with identification of the presymptomatic treatment window becoming a key factor in improving prognosis. The recommendation statement issued by the US Preventive Services Task Force provides policy basis for newborn screening. Next generation gene therapy vectors are improving delivery efficiency and targeting specificity, while the convenience of oral small molecule drugs has significantly enhanced patient adherence to long term treatment. Biogen?s nusinersen, as the first approved spinal muscular atrophy medicine, has received regulatory approval in multiple countries and regions. Novartis?s onasemnogene abeparvovec, as a one time intravenous gene therapy, represents a curative treatment direction. Roche?s risdiplam, as an orally administered small molecule drug, has expanded treatment options.
Market Challenges and Risks
The one time treatment cost of gene therapy stands at the peak of the innovative drug pricing system, posing pressure on healthcare payment capacity. Some patients cannot receive gene therapy due to pre existing neutralizing antibodies against adeno associated virus, limiting the eligible population. Long term safety and durability data are still being accumulated, particularly regarding the lifelong impact of gene therapy in pediatric patients requiring extended follow up confirmation. The large scale manufacturing capacity and quality control requirements for viral vectors are demanding, with capacity expansion facing technical bottlenecks. Marketed products face competitive pressure from subsequent generation therapies, with next generation drugs under clinical development.
Downstream Demand Trends
Patients with infantile onset type 1 spinal muscular atrophy show the most urgent need for rapid acting gene therapy, with presymptomatic treatment representing the optimal intervention window. Patients with type 2 and type 3 spinal muscular atrophy show growing demand for long term oral maintenance therapy, with convenience becoming an important consideration. The adult onset type 4 patient population is receiving increased attention for their need to delay disease progression. The expansion of carrier screening and prenatal diagnosis has spurred discussions on preventive interventions. Notably, combination therapy strategies are being explored clinically, combining gene therapy with oral small molecule drugs to pursue additive efficacy.
Regional Trends
The North American market, with its comprehensive newborn screening systems, strong healthcare coverage, and concentration of innovative companies, leads in the commercialization of Spinal Muscular Atrophy Medicines. The European market, influenced by public healthcare budget constraints, applies relatively strict cost effectiveness assessments for medicines, but patient registries and real world evidence accumulation are relatively mature. The Asia Pacific region, benefiting from accelerated review policies for rare disease drugs in countries including China and Japan, is seeing rapid improvement in patient access, with the National Medical Products Administration of China having included multiple Spinal Muscular Atrophy Medicines in its priority review channel.
LP Information, Inc. (LPI) ' newest research report, the ?Spinal Muscular Atrophy Medicine Industry Forecast? looks at past sales and reviews total world Spinal Muscular Atrophy Medicine sales in 2025, providing a comprehensive analysis by region and market sector of projected Spinal Muscular Atrophy Medicine sales for 2026 through 2032. With Spinal Muscular Atrophy Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Spinal Muscular Atrophy Medicine industry.
This Insight Report provides a comprehensive analysis of the global Spinal Muscular Atrophy Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Spinal Muscular Atrophy Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Spinal Muscular Atrophy Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Spinal Muscular Atrophy Medicine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Spinal Muscular Atrophy Medicine.
This report presents a comprehensive overview, market shares, and growth opportunities of Spinal Muscular Atrophy Medicine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Spinal Muscular Atrophy Medicine market?
What factors are driving Spinal Muscular Atrophy Medicine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Spinal Muscular Atrophy Medicine market opportunities vary by end market size?
How does Spinal Muscular Atrophy Medicine break out by Type, by Application?
Spinal Muscular Atrophy Medicine refers to a general category of pharmaceutical products used for the treatment of spinal muscular atrophy, a rare inherited neuromuscular disease. Spinal muscular atrophy is an autosomal recessive disorder primarily caused by homozygous deletion or mutation of the survival motor neuron 1 gene, leading to deficiency of survival motor neuron protein function, which in turn triggers degeneration of spinal cord anterior horn motor neurons and results in progressive muscle weakness and atrophy in patients. The severity of the disease is inversely correlated with survival motor neuron 2 gene copy number, with fewer copies leading to more severe disease. From an industrial attribute perspective, Spinal Muscular Atrophy Medicine sits at the intersection of gene therapy, antisense oligonucleotide technology, small molecule drug development, and rare disease treatment. Three disease modifying therapies have been approved globally, each increasing functional survival motor neuron protein levels through different mechanisms. The core value of these drugs lies in fundamentally changing the natural history of spinal muscular atrophy, particularly enabling near normal motor development in children treated during the presymptomatic stage.
Market Development Opportunities and Main Drivers
The global expansion of newborn screening programs has promoted early diagnosis of spinal muscular atrophy, with identification of the presymptomatic treatment window becoming a key factor in improving prognosis. The recommendation statement issued by the US Preventive Services Task Force provides policy basis for newborn screening. Next generation gene therapy vectors are improving delivery efficiency and targeting specificity, while the convenience of oral small molecule drugs has significantly enhanced patient adherence to long term treatment. Biogen?s nusinersen, as the first approved spinal muscular atrophy medicine, has received regulatory approval in multiple countries and regions. Novartis?s onasemnogene abeparvovec, as a one time intravenous gene therapy, represents a curative treatment direction. Roche?s risdiplam, as an orally administered small molecule drug, has expanded treatment options.
Market Challenges and Risks
The one time treatment cost of gene therapy stands at the peak of the innovative drug pricing system, posing pressure on healthcare payment capacity. Some patients cannot receive gene therapy due to pre existing neutralizing antibodies against adeno associated virus, limiting the eligible population. Long term safety and durability data are still being accumulated, particularly regarding the lifelong impact of gene therapy in pediatric patients requiring extended follow up confirmation. The large scale manufacturing capacity and quality control requirements for viral vectors are demanding, with capacity expansion facing technical bottlenecks. Marketed products face competitive pressure from subsequent generation therapies, with next generation drugs under clinical development.
Downstream Demand Trends
Patients with infantile onset type 1 spinal muscular atrophy show the most urgent need for rapid acting gene therapy, with presymptomatic treatment representing the optimal intervention window. Patients with type 2 and type 3 spinal muscular atrophy show growing demand for long term oral maintenance therapy, with convenience becoming an important consideration. The adult onset type 4 patient population is receiving increased attention for their need to delay disease progression. The expansion of carrier screening and prenatal diagnosis has spurred discussions on preventive interventions. Notably, combination therapy strategies are being explored clinically, combining gene therapy with oral small molecule drugs to pursue additive efficacy.
Regional Trends
The North American market, with its comprehensive newborn screening systems, strong healthcare coverage, and concentration of innovative companies, leads in the commercialization of Spinal Muscular Atrophy Medicines. The European market, influenced by public healthcare budget constraints, applies relatively strict cost effectiveness assessments for medicines, but patient registries and real world evidence accumulation are relatively mature. The Asia Pacific region, benefiting from accelerated review policies for rare disease drugs in countries including China and Japan, is seeing rapid improvement in patient access, with the National Medical Products Administration of China having included multiple Spinal Muscular Atrophy Medicines in its priority review channel.
LP Information, Inc. (LPI) ' newest research report, the ?Spinal Muscular Atrophy Medicine Industry Forecast? looks at past sales and reviews total world Spinal Muscular Atrophy Medicine sales in 2025, providing a comprehensive analysis by region and market sector of projected Spinal Muscular Atrophy Medicine sales for 2026 through 2032. With Spinal Muscular Atrophy Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Spinal Muscular Atrophy Medicine industry.
This Insight Report provides a comprehensive analysis of the global Spinal Muscular Atrophy Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Spinal Muscular Atrophy Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Spinal Muscular Atrophy Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Spinal Muscular Atrophy Medicine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Spinal Muscular Atrophy Medicine.
This report presents a comprehensive overview, market shares, and growth opportunities of Spinal Muscular Atrophy Medicine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Gene Replacement Drug
- Antisense Oligonucleotide Drug
- Small Molecule Splicing Modifier Drug
- Muscle Targeted Drug
- Intrathecal Injection Drug
- Intravenous Infusion Drug
- Oral Drug
- Vector Based Drug
- Non Vector Drug
- Hospital
- Pharmacy
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Biogen
- Novartis
- Roche
- Sanofi
- Ionis Pharma
- Genethon
- Scholar Rock
- AskBio
- Pfizer
- PTC Therapeutics
- Genecradle Therapeutics
- Romics
What is the 10-year outlook for the global Spinal Muscular Atrophy Medicine market?
What factors are driving Spinal Muscular Atrophy Medicine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Spinal Muscular Atrophy Medicine market opportunities vary by end market size?
How does Spinal Muscular Atrophy Medicine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Spinal Muscular Atrophy Medicine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Spinal Muscular Atrophy Medicine by Country/Region, 2021, 2025 & 2032
2.2 Spinal Muscular Atrophy Medicine Segment by Type
2.2.1 Gene Replacement Drug
2.2.2 Antisense Oligonucleotide Drug
2.2.3 Small Molecule Splicing Modifier Drug
2.2.4 Muscle Targeted Drug
2.2.5 Spinal Muscular Atrophy Medicine Sales by Type
2.2.5.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026)
2.2.5.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Spinal Muscular Atrophy Medicine Sale Price by Type (2021-2026)
2.3 Spinal Muscular Atrophy Medicine Segment by Administration Method
2.3.1 Intrathecal Injection Drug
2.3.2 Intravenous Infusion Drug
2.3.3 Oral Drug
2.3.4 Spinal Muscular Atrophy Medicine Sales by Administration Method
2.3.4.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Administration Method (2021-2026)
2.3.4.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Administration Method (2021-2026)
2.3.4.3 Global Spinal Muscular Atrophy Medicine Sale Price by Administration Method (2021-2026)
2.4 Spinal Muscular Atrophy Medicine Segment by Delivery Vehicle
2.4.1 Vector Based Drug
2.4.2 Non Vector Drug
2.4.3 Spinal Muscular Atrophy Medicine Sales by Delivery Vehicle
2.4.3.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Delivery Vehicle (2021-2026)
2.4.3.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Delivery Vehicle (2021-2026)
2.4.3.3 Global Spinal Muscular Atrophy Medicine Sale Price by Delivery Vehicle (2021-2026)
2.5 Spinal Muscular Atrophy Medicine Segment by Application
2.5.1 Hospital
2.5.2 Pharmacy
2.5.3 Others
2.5.4 Spinal Muscular Atrophy Medicine Sales by Application
2.5.4.1 Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2021-2026)
2.5.4.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Spinal Muscular Atrophy Medicine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Spinal Muscular Atrophy Medicine Breakdown Data by Company
3.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Company (2021-2026)
3.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Company (2021-2026)
3.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Company (2021-2026)
3.2.1 Global Spinal Muscular Atrophy Medicine Revenue by Company (2021-2026)
3.2.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company (2021-2026)
3.3 Global Spinal Muscular Atrophy Medicine Sale Price by Company
3.4 Key Manufacturers Spinal Muscular Atrophy Medicine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Spinal Muscular Atrophy Medicine Product Location Distribution
3.4.2 Players Spinal Muscular Atrophy Medicine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SPINAL MUSCULAR ATROPHY MEDICINE BY GEOGRAPHIC REGION
4.1 World Historic Spinal Muscular Atrophy Medicine Market Size by Geographic Region (2021-2026)
4.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Spinal Muscular Atrophy Medicine Market Size by Country/Region (2021-2026)
4.2.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Spinal Muscular Atrophy Medicine Sales Growth
4.4 APAC Spinal Muscular Atrophy Medicine Sales Growth
4.5 Europe Spinal Muscular Atrophy Medicine Sales Growth
4.6 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Growth
5 AMERICAS
5.1 Americas Spinal Muscular Atrophy Medicine Sales by Country
5.1.1 Americas Spinal Muscular Atrophy Medicine Sales by Country (2021-2026)
5.1.2 Americas Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026)
5.2 Americas Spinal Muscular Atrophy Medicine Sales by Type (2021-2026)
5.3 Americas Spinal Muscular Atrophy Medicine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Spinal Muscular Atrophy Medicine Sales by Region
6.1.1 APAC Spinal Muscular Atrophy Medicine Sales by Region (2021-2026)
6.1.2 APAC Spinal Muscular Atrophy Medicine Revenue by Region (2021-2026)
6.2 APAC Spinal Muscular Atrophy Medicine Sales by Type (2021-2026)
6.3 APAC Spinal Muscular Atrophy Medicine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Spinal Muscular Atrophy Medicine by Country
7.1.1 Europe Spinal Muscular Atrophy Medicine Sales by Country (2021-2026)
7.1.2 Europe Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026)
7.2 Europe Spinal Muscular Atrophy Medicine Sales by Type (2021-2026)
7.3 Europe Spinal Muscular Atrophy Medicine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Spinal Muscular Atrophy Medicine by Country
8.1.1 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026)
8.2 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Type (2021-2026)
8.3 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Spinal Muscular Atrophy Medicine
10.3 Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine
10.4 Industry Chain Structure of Spinal Muscular Atrophy Medicine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Spinal Muscular Atrophy Medicine Distributors
11.3 Spinal Muscular Atrophy Medicine Customer
12 WORLD FORECAST REVIEW FOR SPINAL MUSCULAR ATROPHY MEDICINE BY GEOGRAPHIC REGION
12.1 Global Spinal Muscular Atrophy Medicine Market Size Forecast by Region
12.1.1 Global Spinal Muscular Atrophy Medicine Forecast by Region (2027-2032)
12.1.2 Global Spinal Muscular Atrophy Medicine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Spinal Muscular Atrophy Medicine Forecast by Type (2027-2032)
12.7 Global Spinal Muscular Atrophy Medicine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Biogen
13.1.1 Biogen Company Information
13.1.2 Biogen Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.1.3 Biogen Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Biogen Main Business Overview
13.1.5 Biogen Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.2.3 Novartis Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.3.3 Roche Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.4.3 Sanofi Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 Ionis Pharma
13.5.1 Ionis Pharma Company Information
13.5.2 Ionis Pharma Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.5.3 Ionis Pharma Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Ionis Pharma Main Business Overview
13.5.5 Ionis Pharma Latest Developments
13.6 Genethon
13.6.1 Genethon Company Information
13.6.2 Genethon Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Genethon Main Business Overview
13.6.5 Genethon Latest Developments
13.7 Scholar Rock
13.7.1 Scholar Rock Company Information
13.7.2 Scholar Rock Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.7.3 Scholar Rock Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Scholar Rock Main Business Overview
13.7.5 Scholar Rock Latest Developments
13.8 AskBio
13.8.1 AskBio Company Information
13.8.2 AskBio Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.8.3 AskBio Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 AskBio Main Business Overview
13.8.5 AskBio Latest Developments
13.9 Pfizer
13.9.1 Pfizer Company Information
13.9.2 Pfizer Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.9.3 Pfizer Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Pfizer Main Business Overview
13.9.5 Pfizer Latest Developments
13.10 PTC Therapeutics
13.10.1 PTC Therapeutics Company Information
13.10.2 PTC Therapeutics Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.10.3 PTC Therapeutics Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 PTC Therapeutics Main Business Overview
13.10.5 PTC Therapeutics Latest Developments
13.11 Genecradle Therapeutics
13.11.1 Genecradle Therapeutics Company Information
13.11.2 Genecradle Therapeutics Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.11.3 Genecradle Therapeutics Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Genecradle Therapeutics Main Business Overview
13.11.5 Genecradle Therapeutics Latest Developments
13.12 Romics
13.12.1 Romics Company Information
13.12.2 Romics Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.12.3 Romics Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Romics Main Business Overview
13.12.5 Romics Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Spinal Muscular Atrophy Medicine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Spinal Muscular Atrophy Medicine by Country/Region, 2021, 2025 & 2032
2.2 Spinal Muscular Atrophy Medicine Segment by Type
2.2.1 Gene Replacement Drug
2.2.2 Antisense Oligonucleotide Drug
2.2.3 Small Molecule Splicing Modifier Drug
2.2.4 Muscle Targeted Drug
2.2.5 Spinal Muscular Atrophy Medicine Sales by Type
2.2.5.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026)
2.2.5.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Spinal Muscular Atrophy Medicine Sale Price by Type (2021-2026)
2.3 Spinal Muscular Atrophy Medicine Segment by Administration Method
2.3.1 Intrathecal Injection Drug
2.3.2 Intravenous Infusion Drug
2.3.3 Oral Drug
2.3.4 Spinal Muscular Atrophy Medicine Sales by Administration Method
2.3.4.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Administration Method (2021-2026)
2.3.4.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Administration Method (2021-2026)
2.3.4.3 Global Spinal Muscular Atrophy Medicine Sale Price by Administration Method (2021-2026)
2.4 Spinal Muscular Atrophy Medicine Segment by Delivery Vehicle
2.4.1 Vector Based Drug
2.4.2 Non Vector Drug
2.4.3 Spinal Muscular Atrophy Medicine Sales by Delivery Vehicle
2.4.3.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Delivery Vehicle (2021-2026)
2.4.3.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Delivery Vehicle (2021-2026)
2.4.3.3 Global Spinal Muscular Atrophy Medicine Sale Price by Delivery Vehicle (2021-2026)
2.5 Spinal Muscular Atrophy Medicine Segment by Application
2.5.1 Hospital
2.5.2 Pharmacy
2.5.3 Others
2.5.4 Spinal Muscular Atrophy Medicine Sales by Application
2.5.4.1 Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2021-2026)
2.5.4.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Spinal Muscular Atrophy Medicine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Spinal Muscular Atrophy Medicine Breakdown Data by Company
3.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Company (2021-2026)
3.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Company (2021-2026)
3.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Company (2021-2026)
3.2.1 Global Spinal Muscular Atrophy Medicine Revenue by Company (2021-2026)
3.2.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company (2021-2026)
3.3 Global Spinal Muscular Atrophy Medicine Sale Price by Company
3.4 Key Manufacturers Spinal Muscular Atrophy Medicine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Spinal Muscular Atrophy Medicine Product Location Distribution
3.4.2 Players Spinal Muscular Atrophy Medicine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SPINAL MUSCULAR ATROPHY MEDICINE BY GEOGRAPHIC REGION
4.1 World Historic Spinal Muscular Atrophy Medicine Market Size by Geographic Region (2021-2026)
4.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Spinal Muscular Atrophy Medicine Market Size by Country/Region (2021-2026)
4.2.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Spinal Muscular Atrophy Medicine Sales Growth
4.4 APAC Spinal Muscular Atrophy Medicine Sales Growth
4.5 Europe Spinal Muscular Atrophy Medicine Sales Growth
4.6 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Growth
5 AMERICAS
5.1 Americas Spinal Muscular Atrophy Medicine Sales by Country
5.1.1 Americas Spinal Muscular Atrophy Medicine Sales by Country (2021-2026)
5.1.2 Americas Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026)
5.2 Americas Spinal Muscular Atrophy Medicine Sales by Type (2021-2026)
5.3 Americas Spinal Muscular Atrophy Medicine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Spinal Muscular Atrophy Medicine Sales by Region
6.1.1 APAC Spinal Muscular Atrophy Medicine Sales by Region (2021-2026)
6.1.2 APAC Spinal Muscular Atrophy Medicine Revenue by Region (2021-2026)
6.2 APAC Spinal Muscular Atrophy Medicine Sales by Type (2021-2026)
6.3 APAC Spinal Muscular Atrophy Medicine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Spinal Muscular Atrophy Medicine by Country
7.1.1 Europe Spinal Muscular Atrophy Medicine Sales by Country (2021-2026)
7.1.2 Europe Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026)
7.2 Europe Spinal Muscular Atrophy Medicine Sales by Type (2021-2026)
7.3 Europe Spinal Muscular Atrophy Medicine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Spinal Muscular Atrophy Medicine by Country
8.1.1 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026)
8.2 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Type (2021-2026)
8.3 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Spinal Muscular Atrophy Medicine
10.3 Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine
10.4 Industry Chain Structure of Spinal Muscular Atrophy Medicine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Spinal Muscular Atrophy Medicine Distributors
11.3 Spinal Muscular Atrophy Medicine Customer
12 WORLD FORECAST REVIEW FOR SPINAL MUSCULAR ATROPHY MEDICINE BY GEOGRAPHIC REGION
12.1 Global Spinal Muscular Atrophy Medicine Market Size Forecast by Region
12.1.1 Global Spinal Muscular Atrophy Medicine Forecast by Region (2027-2032)
12.1.2 Global Spinal Muscular Atrophy Medicine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Spinal Muscular Atrophy Medicine Forecast by Type (2027-2032)
12.7 Global Spinal Muscular Atrophy Medicine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Biogen
13.1.1 Biogen Company Information
13.1.2 Biogen Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.1.3 Biogen Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Biogen Main Business Overview
13.1.5 Biogen Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.2.3 Novartis Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.3.3 Roche Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.4.3 Sanofi Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 Ionis Pharma
13.5.1 Ionis Pharma Company Information
13.5.2 Ionis Pharma Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.5.3 Ionis Pharma Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Ionis Pharma Main Business Overview
13.5.5 Ionis Pharma Latest Developments
13.6 Genethon
13.6.1 Genethon Company Information
13.6.2 Genethon Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Genethon Main Business Overview
13.6.5 Genethon Latest Developments
13.7 Scholar Rock
13.7.1 Scholar Rock Company Information
13.7.2 Scholar Rock Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.7.3 Scholar Rock Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Scholar Rock Main Business Overview
13.7.5 Scholar Rock Latest Developments
13.8 AskBio
13.8.1 AskBio Company Information
13.8.2 AskBio Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.8.3 AskBio Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 AskBio Main Business Overview
13.8.5 AskBio Latest Developments
13.9 Pfizer
13.9.1 Pfizer Company Information
13.9.2 Pfizer Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.9.3 Pfizer Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Pfizer Main Business Overview
13.9.5 Pfizer Latest Developments
13.10 PTC Therapeutics
13.10.1 PTC Therapeutics Company Information
13.10.2 PTC Therapeutics Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.10.3 PTC Therapeutics Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 PTC Therapeutics Main Business Overview
13.10.5 PTC Therapeutics Latest Developments
13.11 Genecradle Therapeutics
13.11.1 Genecradle Therapeutics Company Information
13.11.2 Genecradle Therapeutics Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.11.3 Genecradle Therapeutics Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Genecradle Therapeutics Main Business Overview
13.11.5 Genecradle Therapeutics Latest Developments
13.12 Romics
13.12.1 Romics Company Information
13.12.2 Romics Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.12.3 Romics Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Romics Main Business Overview
13.12.5 Romics Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Spinal Muscular Atrophy Medicine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Spinal Muscular Atrophy Medicine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Gene Replacement Drug
Table 4. Major Players of Antisense Oligonucleotide Drug
Table 5. Major Players of Small Molecule Splicing Modifier Drug
Table 6. Major Players of Muscle Targeted Drug
Table 7. Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (K Dose)
Table 8. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026)
Table 9. Global Spinal Muscular Atrophy Medicine Revenue by Type (2021-2026) & ($ million)
Table 10. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2026)
Table 11. Global Spinal Muscular Atrophy Medicine Sale Price by Type (2021-2026) & (US$/Dose)
Table 12. Major Players of Intrathecal Injection Drug
Table 13. Major Players of Intravenous Infusion Drug
Table 14. Major Players of Oral Drug
Table 15. Global Spinal Muscular Atrophy Medicine Sales by Administration Method (2021-2026) & (K Dose)
Table 16. Global Spinal Muscular Atrophy Medicine Sales Market Share by Administration Method (2021-2026)
Table 17. Global Spinal Muscular Atrophy Medicine Revenue by Administration Method (2021-2026) & ($ million)
Table 18. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Administration Method (2021-2026)
Table 19. Global Spinal Muscular Atrophy Medicine Sale Price by Administration Method (2021-2026) & (US$/Dose)
Table 20. Major Players of Vector Based Drug
Table 21. Major Players of Non Vector Drug
Table 22. Global Spinal Muscular Atrophy Medicine Sales by Delivery Vehicle (2021-2026) & (K Dose)
Table 23. Global Spinal Muscular Atrophy Medicine Sales Market Share by Delivery Vehicle (2021-2026)
Table 24. Global Spinal Muscular Atrophy Medicine Revenue by Delivery Vehicle (2021-2026) & ($ million)
Table 25. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Delivery Vehicle (2021-2026)
Table 26. Global Spinal Muscular Atrophy Medicine Sale Price by Delivery Vehicle (2021-2026) & (US$/Dose)
Table 27. Global Spinal Muscular Atrophy Medicine Sale by Application (2021-2026) & (K Dose)
Table 28. Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2021-2026)
Table 29. Global Spinal Muscular Atrophy Medicine Revenue by Application (2021-2026) & ($ million)
Table 30. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2021-2026)
Table 31. Global Spinal Muscular Atrophy Medicine Sale Price by Application (2021-2026) & (US$/Dose)
Table 32. Global Spinal Muscular Atrophy Medicine Sales by Company (2021-2026) & (K Dose)
Table 33. Global Spinal Muscular Atrophy Medicine Sales Market Share by Company (2021-2026)
Table 34. Global Spinal Muscular Atrophy Medicine Revenue by Company (2021-2026) & ($ millions)
Table 35. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company (2021-2026)
Table 36. Global Spinal Muscular Atrophy Medicine Sale Price by Company (2021-2026) & (US$/Dose)
Table 37. Key Manufacturers Spinal Muscular Atrophy Medicine Producing Area Distribution and Sales Area
Table 38. Players Spinal Muscular Atrophy Medicine Products Offered
Table 39. Spinal Muscular Atrophy Medicine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 40. New Products and Potential Entrants
Table 41. Market M&A Activity & Strategy
Table 42. Global Spinal Muscular Atrophy Medicine Sales by Geographic Region (2021-2026) & (K Dose)
Table 43. Global Spinal Muscular Atrophy Medicine Sales Market Share Geographic Region (2021-2026)
Table 44. Global Spinal Muscular Atrophy Medicine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 45. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Geographic Region (2021-2026)
Table 46. Global Spinal Muscular Atrophy Medicine Sales by Country/Region (2021-2026) & (K Dose)
Table 47. Global Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2021-2026)
Table 48. Global Spinal Muscular Atrophy Medicine Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (K Dose)
Table 51. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2026)
Table 52. Americas Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026) & ($ millions)
Table 53. Americas Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (K Dose)
Table 54. Americas Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (K Dose)
Table 55. APAC Spinal Muscular Atrophy Medicine Sales by Region (2021-2026) & (K Dose)
Table 56. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Region (2021-2026)
Table 57. APAC Spinal Muscular Atrophy Medicine Revenue by Region (2021-2026) & ($ millions)
Table 58. APAC Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (K Dose)
Table 59. APAC Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (K Dose)
Table 60. Europe Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (K Dose)
Table 61. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026) & ($ millions)
Table 62. Europe Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (K Dose)
Table 63. Europe Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (K Dose)
Table 64. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (K Dose)
Table 65. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2026)
Table 66. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (K Dose)
Table 67. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (K Dose)
Table 68. Key Market Drivers & Growth Opportunities of Spinal Muscular Atrophy Medicine
Table 69. Key Market Challenges & Risks of Spinal Muscular Atrophy Medicine
Table 70. Key Industry Trends of Spinal Muscular Atrophy Medicine
Table 71. Spinal Muscular Atrophy Medicine Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Spinal Muscular Atrophy Medicine Distributors List
Table 74. Spinal Muscular Atrophy Medicine Customer List
Table 75. Global Spinal Muscular Atrophy Medicine Sales Forecast by Region (2027-2032) & (K Dose)
Table 76. Global Spinal Muscular Atrophy Medicine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Americas Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032) & (K Dose)
Table 78. Americas Spinal Muscular Atrophy Medicine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. APAC Spinal Muscular Atrophy Medicine Sales Forecast by Region (2027-2032) & (K Dose)
Table 80. APAC Spinal Muscular Atrophy Medicine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Europe Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Europe Spinal Muscular Atrophy Medicine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032) & (K Dose)
Table 84. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Global Spinal Muscular Atrophy Medicine Sales Forecast by Type (2027-2032) & (K Dose)
Table 86. Global Spinal Muscular Atrophy Medicine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 87. Global Spinal Muscular Atrophy Medicine Sales Forecast by Application (2027-2032) & (K Dose)
Table 88. Global Spinal Muscular Atrophy Medicine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 89. Biogen Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 90. Biogen Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 91. Biogen Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 92. Biogen Main Business
Table 93. Biogen Latest Developments
Table 94. Novartis Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 95. Novartis Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 96. Novartis Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 97. Novartis Main Business
Table 98. Novartis Latest Developments
Table 99. Roche Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 100. Roche Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 101. Roche Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 102. Roche Main Business
Table 103. Roche Latest Developments
Table 104. Sanofi Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 105. Sanofi Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 106. Sanofi Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. Sanofi Main Business
Table 108. Sanofi Latest Developments
Table 109. Ionis Pharma Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 110. Ionis Pharma Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 111. Ionis Pharma Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. Ionis Pharma Main Business
Table 113. Ionis Pharma Latest Developments
Table 114. Genethon Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 115. Genethon Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 116. Genethon Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. Genethon Main Business
Table 118. Genethon Latest Developments
Table 119. Scholar Rock Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 120. Scholar Rock Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 121. Scholar Rock Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. Scholar Rock Main Business
Table 123. Scholar Rock Latest Developments
Table 124. AskBio Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 125. AskBio Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 126. AskBio Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. AskBio Main Business
Table 128. AskBio Latest Developments
Table 129. Pfizer Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 130. Pfizer Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 131. Pfizer Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 132. Pfizer Main Business
Table 133. Pfizer Latest Developments
Table 134. PTC Therapeutics Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 135. PTC Therapeutics Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 136. PTC Therapeutics Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 137. PTC Therapeutics Main Business
Table 138. PTC Therapeutics Latest Developments
Table 139. Genecradle Therapeutics Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 140. Genecradle Therapeutics Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 141. Genecradle Therapeutics Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 142. Genecradle Therapeutics Main Business
Table 143. Genecradle Therapeutics Latest Developments
Table 144. Romics Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 145. Romics Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 146. Romics Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 147. Romics Main Business
Table 148. Romics Latest Developments
Table 1. Spinal Muscular Atrophy Medicine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Spinal Muscular Atrophy Medicine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Gene Replacement Drug
Table 4. Major Players of Antisense Oligonucleotide Drug
Table 5. Major Players of Small Molecule Splicing Modifier Drug
Table 6. Major Players of Muscle Targeted Drug
Table 7. Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (K Dose)
Table 8. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026)
Table 9. Global Spinal Muscular Atrophy Medicine Revenue by Type (2021-2026) & ($ million)
Table 10. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2026)
Table 11. Global Spinal Muscular Atrophy Medicine Sale Price by Type (2021-2026) & (US$/Dose)
Table 12. Major Players of Intrathecal Injection Drug
Table 13. Major Players of Intravenous Infusion Drug
Table 14. Major Players of Oral Drug
Table 15. Global Spinal Muscular Atrophy Medicine Sales by Administration Method (2021-2026) & (K Dose)
Table 16. Global Spinal Muscular Atrophy Medicine Sales Market Share by Administration Method (2021-2026)
Table 17. Global Spinal Muscular Atrophy Medicine Revenue by Administration Method (2021-2026) & ($ million)
Table 18. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Administration Method (2021-2026)
Table 19. Global Spinal Muscular Atrophy Medicine Sale Price by Administration Method (2021-2026) & (US$/Dose)
Table 20. Major Players of Vector Based Drug
Table 21. Major Players of Non Vector Drug
Table 22. Global Spinal Muscular Atrophy Medicine Sales by Delivery Vehicle (2021-2026) & (K Dose)
Table 23. Global Spinal Muscular Atrophy Medicine Sales Market Share by Delivery Vehicle (2021-2026)
Table 24. Global Spinal Muscular Atrophy Medicine Revenue by Delivery Vehicle (2021-2026) & ($ million)
Table 25. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Delivery Vehicle (2021-2026)
Table 26. Global Spinal Muscular Atrophy Medicine Sale Price by Delivery Vehicle (2021-2026) & (US$/Dose)
Table 27. Global Spinal Muscular Atrophy Medicine Sale by Application (2021-2026) & (K Dose)
Table 28. Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2021-2026)
Table 29. Global Spinal Muscular Atrophy Medicine Revenue by Application (2021-2026) & ($ million)
Table 30. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2021-2026)
Table 31. Global Spinal Muscular Atrophy Medicine Sale Price by Application (2021-2026) & (US$/Dose)
Table 32. Global Spinal Muscular Atrophy Medicine Sales by Company (2021-2026) & (K Dose)
Table 33. Global Spinal Muscular Atrophy Medicine Sales Market Share by Company (2021-2026)
Table 34. Global Spinal Muscular Atrophy Medicine Revenue by Company (2021-2026) & ($ millions)
Table 35. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company (2021-2026)
Table 36. Global Spinal Muscular Atrophy Medicine Sale Price by Company (2021-2026) & (US$/Dose)
Table 37. Key Manufacturers Spinal Muscular Atrophy Medicine Producing Area Distribution and Sales Area
Table 38. Players Spinal Muscular Atrophy Medicine Products Offered
Table 39. Spinal Muscular Atrophy Medicine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 40. New Products and Potential Entrants
Table 41. Market M&A Activity & Strategy
Table 42. Global Spinal Muscular Atrophy Medicine Sales by Geographic Region (2021-2026) & (K Dose)
Table 43. Global Spinal Muscular Atrophy Medicine Sales Market Share Geographic Region (2021-2026)
Table 44. Global Spinal Muscular Atrophy Medicine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 45. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Geographic Region (2021-2026)
Table 46. Global Spinal Muscular Atrophy Medicine Sales by Country/Region (2021-2026) & (K Dose)
Table 47. Global Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2021-2026)
Table 48. Global Spinal Muscular Atrophy Medicine Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (K Dose)
Table 51. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2026)
Table 52. Americas Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026) & ($ millions)
Table 53. Americas Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (K Dose)
Table 54. Americas Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (K Dose)
Table 55. APAC Spinal Muscular Atrophy Medicine Sales by Region (2021-2026) & (K Dose)
Table 56. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Region (2021-2026)
Table 57. APAC Spinal Muscular Atrophy Medicine Revenue by Region (2021-2026) & ($ millions)
Table 58. APAC Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (K Dose)
Table 59. APAC Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (K Dose)
Table 60. Europe Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (K Dose)
Table 61. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2021-2026) & ($ millions)
Table 62. Europe Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (K Dose)
Table 63. Europe Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (K Dose)
Table 64. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (K Dose)
Table 65. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2026)
Table 66. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (K Dose)
Table 67. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (K Dose)
Table 68. Key Market Drivers & Growth Opportunities of Spinal Muscular Atrophy Medicine
Table 69. Key Market Challenges & Risks of Spinal Muscular Atrophy Medicine
Table 70. Key Industry Trends of Spinal Muscular Atrophy Medicine
Table 71. Spinal Muscular Atrophy Medicine Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Spinal Muscular Atrophy Medicine Distributors List
Table 74. Spinal Muscular Atrophy Medicine Customer List
Table 75. Global Spinal Muscular Atrophy Medicine Sales Forecast by Region (2027-2032) & (K Dose)
Table 76. Global Spinal Muscular Atrophy Medicine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Americas Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032) & (K Dose)
Table 78. Americas Spinal Muscular Atrophy Medicine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. APAC Spinal Muscular Atrophy Medicine Sales Forecast by Region (2027-2032) & (K Dose)
Table 80. APAC Spinal Muscular Atrophy Medicine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Europe Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Europe Spinal Muscular Atrophy Medicine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032) & (K Dose)
Table 84. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Global Spinal Muscular Atrophy Medicine Sales Forecast by Type (2027-2032) & (K Dose)
Table 86. Global Spinal Muscular Atrophy Medicine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 87. Global Spinal Muscular Atrophy Medicine Sales Forecast by Application (2027-2032) & (K Dose)
Table 88. Global Spinal Muscular Atrophy Medicine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 89. Biogen Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 90. Biogen Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 91. Biogen Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 92. Biogen Main Business
Table 93. Biogen Latest Developments
Table 94. Novartis Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 95. Novartis Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 96. Novartis Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 97. Novartis Main Business
Table 98. Novartis Latest Developments
Table 99. Roche Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 100. Roche Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 101. Roche Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 102. Roche Main Business
Table 103. Roche Latest Developments
Table 104. Sanofi Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 105. Sanofi Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 106. Sanofi Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. Sanofi Main Business
Table 108. Sanofi Latest Developments
Table 109. Ionis Pharma Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 110. Ionis Pharma Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 111. Ionis Pharma Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. Ionis Pharma Main Business
Table 113. Ionis Pharma Latest Developments
Table 114. Genethon Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 115. Genethon Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 116. Genethon Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. Genethon Main Business
Table 118. Genethon Latest Developments
Table 119. Scholar Rock Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 120. Scholar Rock Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 121. Scholar Rock Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. Scholar Rock Main Business
Table 123. Scholar Rock Latest Developments
Table 124. AskBio Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 125. AskBio Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 126. AskBio Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. AskBio Main Business
Table 128. AskBio Latest Developments
Table 129. Pfizer Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 130. Pfizer Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 131. Pfizer Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 132. Pfizer Main Business
Table 133. Pfizer Latest Developments
Table 134. PTC Therapeutics Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 135. PTC Therapeutics Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 136. PTC Therapeutics Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 137. PTC Therapeutics Main Business
Table 138. PTC Therapeutics Latest Developments
Table 139. Genecradle Therapeutics Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 140. Genecradle Therapeutics Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 141. Genecradle Therapeutics Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 142. Genecradle Therapeutics Main Business
Table 143. Genecradle Therapeutics Latest Developments
Table 144. Romics Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 145. Romics Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 146. Romics Spinal Muscular Atrophy Medicine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 147. Romics Main Business
Table 148. Romics Latest Developments
LIST OF FIGURES
Figure 1. Picture of Spinal Muscular Atrophy Medicine
Figure 2. Spinal Muscular Atrophy Medicine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Spinal Muscular Atrophy Medicine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Spinal Muscular Atrophy Medicine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Spinal Muscular Atrophy Medicine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2025)
Figure 10. Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Gene Replacement Drug
Figure 12. Product Picture of Antisense Oligonucleotide Drug
Figure 13. Product Picture of Small Molecule Splicing Modifier Drug
Figure 14. Product Picture of Muscle Targeted Drug
Figure 15. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type in 2026
Figure 16. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Intrathecal Injection Drug
Figure 18. Product Picture of Intravenous Infusion Drug
Figure 19. Product Picture of Oral Drug
Figure 20. Global Spinal Muscular Atrophy Medicine Sales Market Share by Administration Method in 2026
Figure 21. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Administration Method (2021-2026)
Figure 22. Product Picture of Vector Based Drug
Figure 23. Product Picture of Non Vector Drug
Figure 24. Global Spinal Muscular Atrophy Medicine Sales Market Share by Delivery Vehicle in 2026
Figure 25. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Delivery Vehicle (2021-2026)
Figure 26. Spinal Muscular Atrophy Medicine Consumed in Hospital
Figure 27. Global Spinal Muscular Atrophy Medicine Market: Hospital (2021-2026) & (K Dose)
Figure 28. Spinal Muscular Atrophy Medicine Consumed in Pharmacy
Figure 29. Global Spinal Muscular Atrophy Medicine Market: Pharmacy (2021-2026) & (K Dose)
Figure 30. Spinal Muscular Atrophy Medicine Consumed in Others
Figure 31. Global Spinal Muscular Atrophy Medicine Market: Others (2021-2026) & (K Dose)
Figure 32. Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2025)
Figure 33. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application in 2025
Figure 34. Spinal Muscular Atrophy Medicine Sales by Company in 2025 (K Dose)
Figure 35. Global Spinal Muscular Atrophy Medicine Sales Market Share by Company in 2025
Figure 36. Spinal Muscular Atrophy Medicine Revenue by Company in 2025 ($ millions)
Figure 37. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company in 2025
Figure 38. Global Spinal Muscular Atrophy Medicine Sales Market Share by Geographic Region (2021-2026)
Figure 39. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Geographic Region in 2025
Figure 40. Americas Spinal Muscular Atrophy Medicine Sales 2021-2026 (K Dose)
Figure 41. Americas Spinal Muscular Atrophy Medicine Revenue 2021-2026 ($ millions)
Figure 42. APAC Spinal Muscular Atrophy Medicine Sales 2021-2026 (K Dose)
Figure 43. APAC Spinal Muscular Atrophy Medicine Revenue 2021-2026 ($ millions)
Figure 44. Europe Spinal Muscular Atrophy Medicine Sales 2021-2026 (K Dose)
Figure 45. Europe Spinal Muscular Atrophy Medicine Revenue 2021-2026 ($ millions)
Figure 46. Middle East & Africa Spinal Muscular Atrophy Medicine Sales 2021-2026 (K Dose)
Figure 47. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue 2021-2026 ($ millions)
Figure 48. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2025
Figure 49. Americas Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2026)
Figure 50. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026)
Figure 51. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2026)
Figure 52. United States Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 53. Canada Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 54. Mexico Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 55. Brazil Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 56. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2025
Figure 57. APAC Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2021-2026)
Figure 58. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026)
Figure 59. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2026)
Figure 60. China Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 61. Japan Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 62. South Korea Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 63. Southeast Asia Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 64. India Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 65. Australia Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 66. China Taiwan Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 67. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2025
Figure 68. Europe Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2026)
Figure 69. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026)
Figure 70. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2026)
Figure 71. Germany Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 72. France Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 73. UK Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 74. Italy Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 75. Russia Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 76. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2026)
Figure 77. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026)
Figure 78. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2026)
Figure 79. Egypt Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 80. South Africa Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 81. Israel Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 82. Turkey Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 83. GCC Countries Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 84. Manufacturing Cost Structure Analysis of Spinal Muscular Atrophy Medicine in 2026
Figure 85. Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine
Figure 86. Industry Chain Structure of Spinal Muscular Atrophy Medicine
Figure 87. Channels of Distribution
Figure 88. Global Spinal Muscular Atrophy Medicine Sales Market Forecast by Region (2027-2032)
Figure 89. Global Spinal Muscular Atrophy Medicine Revenue Market Share Forecast by Region (2027-2032)
Figure 90. Global Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Type (2027-2032)
Figure 91. Global Spinal Muscular Atrophy Medicine Revenue Market Share Forecast by Type (2027-2032)
Figure 92. Global Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Application (2027-2032)
Figure 93. Global Spinal Muscular Atrophy Medicine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Spinal Muscular Atrophy Medicine
Figure 2. Spinal Muscular Atrophy Medicine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Spinal Muscular Atrophy Medicine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Spinal Muscular Atrophy Medicine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Spinal Muscular Atrophy Medicine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2025)
Figure 10. Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Gene Replacement Drug
Figure 12. Product Picture of Antisense Oligonucleotide Drug
Figure 13. Product Picture of Small Molecule Splicing Modifier Drug
Figure 14. Product Picture of Muscle Targeted Drug
Figure 15. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type in 2026
Figure 16. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Intrathecal Injection Drug
Figure 18. Product Picture of Intravenous Infusion Drug
Figure 19. Product Picture of Oral Drug
Figure 20. Global Spinal Muscular Atrophy Medicine Sales Market Share by Administration Method in 2026
Figure 21. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Administration Method (2021-2026)
Figure 22. Product Picture of Vector Based Drug
Figure 23. Product Picture of Non Vector Drug
Figure 24. Global Spinal Muscular Atrophy Medicine Sales Market Share by Delivery Vehicle in 2026
Figure 25. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Delivery Vehicle (2021-2026)
Figure 26. Spinal Muscular Atrophy Medicine Consumed in Hospital
Figure 27. Global Spinal Muscular Atrophy Medicine Market: Hospital (2021-2026) & (K Dose)
Figure 28. Spinal Muscular Atrophy Medicine Consumed in Pharmacy
Figure 29. Global Spinal Muscular Atrophy Medicine Market: Pharmacy (2021-2026) & (K Dose)
Figure 30. Spinal Muscular Atrophy Medicine Consumed in Others
Figure 31. Global Spinal Muscular Atrophy Medicine Market: Others (2021-2026) & (K Dose)
Figure 32. Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2025)
Figure 33. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application in 2025
Figure 34. Spinal Muscular Atrophy Medicine Sales by Company in 2025 (K Dose)
Figure 35. Global Spinal Muscular Atrophy Medicine Sales Market Share by Company in 2025
Figure 36. Spinal Muscular Atrophy Medicine Revenue by Company in 2025 ($ millions)
Figure 37. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company in 2025
Figure 38. Global Spinal Muscular Atrophy Medicine Sales Market Share by Geographic Region (2021-2026)
Figure 39. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Geographic Region in 2025
Figure 40. Americas Spinal Muscular Atrophy Medicine Sales 2021-2026 (K Dose)
Figure 41. Americas Spinal Muscular Atrophy Medicine Revenue 2021-2026 ($ millions)
Figure 42. APAC Spinal Muscular Atrophy Medicine Sales 2021-2026 (K Dose)
Figure 43. APAC Spinal Muscular Atrophy Medicine Revenue 2021-2026 ($ millions)
Figure 44. Europe Spinal Muscular Atrophy Medicine Sales 2021-2026 (K Dose)
Figure 45. Europe Spinal Muscular Atrophy Medicine Revenue 2021-2026 ($ millions)
Figure 46. Middle East & Africa Spinal Muscular Atrophy Medicine Sales 2021-2026 (K Dose)
Figure 47. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue 2021-2026 ($ millions)
Figure 48. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2025
Figure 49. Americas Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2026)
Figure 50. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026)
Figure 51. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2026)
Figure 52. United States Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 53. Canada Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 54. Mexico Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 55. Brazil Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 56. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2025
Figure 57. APAC Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2021-2026)
Figure 58. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026)
Figure 59. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2026)
Figure 60. China Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 61. Japan Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 62. South Korea Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 63. Southeast Asia Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 64. India Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 65. Australia Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 66. China Taiwan Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 67. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2025
Figure 68. Europe Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2021-2026)
Figure 69. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026)
Figure 70. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2026)
Figure 71. Germany Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 72. France Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 73. UK Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 74. Italy Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 75. Russia Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 76. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2026)
Figure 77. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Type (2021-2026)
Figure 78. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Application (2021-2026)
Figure 79. Egypt Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 80. South Africa Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 81. Israel Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 82. Turkey Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 83. GCC Countries Spinal Muscular Atrophy Medicine Revenue Growth 2021-2026 ($ millions)
Figure 84. Manufacturing Cost Structure Analysis of Spinal Muscular Atrophy Medicine in 2026
Figure 85. Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine
Figure 86. Industry Chain Structure of Spinal Muscular Atrophy Medicine
Figure 87. Channels of Distribution
Figure 88. Global Spinal Muscular Atrophy Medicine Sales Market Forecast by Region (2027-2032)
Figure 89. Global Spinal Muscular Atrophy Medicine Revenue Market Share Forecast by Region (2027-2032)
Figure 90. Global Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Type (2027-2032)
Figure 91. Global Spinal Muscular Atrophy Medicine Revenue Market Share Forecast by Type (2027-2032)
Figure 92. Global Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Application (2027-2032)
Figure 93. Global Spinal Muscular Atrophy Medicine Revenue Market Share Forecast by Application (2027-2032)
